GlassScriptPhysician profile
Hector Collantes
NPI 1255431722
$7,009.46
in general payments reported to CMS, 2019-2025
35 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,660 · 2022: $2,053 · 2023: $1,023 · 2024: $1,248 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,392.11 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $1,273.74 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,052.68 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $681.98 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $426.23 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $400.09 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Alexion Pharmaceuticals, INC. | $172.11 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.29 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $154.85 | 2022 | |
| Madrigal Pharmaceuticals | $146.69 | 2024-2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $133.95 | 2021-2022 | |
| Pfizer INC. | $123.04 | 2021-2025 | |
| Esperion Therapeutics, INC. | $117.14 | 2022 | |
| Amgen INC. | $87.36 | 2024-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $83.39 | 2021-2025 | Gardasil 9, Capvaxive, Vaxelis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $77.83 | 2022-2023 | Freestyle Libre 2 |
| Sanofi Pasteur INC. | $52.46 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $47.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.72 | 2022 | |
| Glaxosmithkline, LLC. | $43.06 | 2023-2024 | Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $41.63 | 2023-2025 | Jynarque, Rexulti |
| Idorsia Pharmaceuticals US INC | $37.59 | 2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $27.75 | 2025 | |
| Exact Sciences Corporation | $24.76 | 2024 | Cologuard Collection Kit |
| Sun Pharmaceutical Industries INC. | $24.67 | 2021 | |
| Hologic Sales and Service, LLC | $24.60 | 2025 | Aptima, Thinprep 2000 Processor |
| Amarin Pharma, INC. | $22.39 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.36 | 2023 | Gvoke Hypopen |
| Shield Therapeutics INC | $22.15 | 2023 | Accrufer |
| Horizon Therapeutics Plc | $19.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.04 | 2021 | |
| Optos, INC. | $16.52 | 2021 | |
| Eisai INC. | $15.22 | 2021 | |
| Cequr Corporation | $13.99 | 2024 | Cequr Simplicity |
| Astellas Pharma US INC | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Collantes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.